MAPK1 and neoplasm: To test whether versican G3 expression enhanced EGFR/ERK signaling pathway in vivo, paraffin sections of primary tumor, lung, and spine were stained with H&E and immunohistochemistry stained with anti-pERK and and anti-G3 (4B6) antibodies.